{"id":812,"date":"2026-10-20T03:32:17","date_gmt":"2026-10-20T01:32:17","guid":{"rendered":"http:\/\/novameds.local\/de\/?post_type=product&#038;p=812"},"modified":"2026-10-20T04:00:30","modified_gmt":"2026-10-20T02:00:30","slug":"catalog-ace-031-1-mg","status":"publish","type":"product","link":"https:\/\/novameds.health\/de\/produkt\/catalog-ace-031-1-mg\/","title":{"rendered":"ACE-031 1 mg"},"content":{"rendered":"<section id=\"composition\" data-nav=\"Zusammensetzung und Produktdetails\">\n<h2>Zusammensetzung und Produktdetails<\/h2>\n<div class=\"nm-catalog-document\">\n<div>\n<h2>\u00dcbersicht<\/h2>\n<div>\n<p>ACE-031 (Ramatercept) is a soluble fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to a human IgG1-Fc region. By acting as a decoy receptor (&#8218;ligand trap&#8216;), it sequesters multiple TGF-\u03b2 superfamily ligands \u2014 myostatin, activin A\/B, GDF-11, BMP-9, BMP-10 \u2014 preventing their binding to native ACVR2B.<\/p>\n<p>Research applications include broad TGF-\u03b2 superfamily pathway investigation, myostatin\/activin pathway dissection, and ligand trap pharmacology.<\/p>\n<ul>\n<li> <span><b>High Purity<\/b> \u2013 99% Purity Guaranteed<\/span><\/li>\n<li> Independently Lab Tested<\/li>\n<li> Research Grade Quality<\/li>\n<li> For Laboratory Research Use Only<\/li>\n<\/ul><\/div>\n<div>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/118732224\" target=\"_blank\" rel=\"noopener noreferrer\">Molekulardaten bei PubChem<\/a><\/p>\n<div>\n<div><span>ACE-031 1mg<\/span><span>1 vial | KIT (10 vials)<\/span><\/div>\n<\/div><\/div>\n<\/p><\/div>\n<div>\n<h2>Eigenschaften<\/h2>\n<div class=\"nm-catalog-table\" tabindex=\"0\" role=\"region\" aria-label=\"Product data\">\n<table>\n<tbody>\n<tr>\n<th>Chemical Formula<\/th>\n<td>C133H227N43O33<\/td>\n<\/tr>\n<tr>\n<th>Synonyms<\/th>\n<td>UNII-U8DGS69FVC, Myostatin inhibitory peptide 7, U8DGS69FVC, CHEMBL3410227, Ala-Trp-Arg-Gln-Asn-Thr-Arg-Tyr-Ser-Arg-Ile-Glu-Ala-Ile-Lys-Ile-Gln-Ile-Leu-Ser-Lys-Leu-Arg-Leu-NH2, BDBM50071379, ACE-031 Myostatin inhibitory peptide 7<\/td>\n<\/tr>\n<tr>\n<th>Molar Mass<\/th>\n<td>2956.5 g\/mol<\/td>\n<\/tr>\n<tr>\n<th>CAS Number<\/th>\n<td>1621169-52-5<\/td>\n<\/tr>\n<tr>\n<th>PubChem CID<\/th>\n<td>118732224<\/td>\n<\/tr>\n<tr>\n<th>Verf\u00fcgbare Formate<\/th>\n<td>1 vial \u00b7 KIT (10 vials)<\/td>\n<\/tr>\n<tr>\n<th>Shelf Life<\/th>\n<td>24 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n<div>\n<h2>Forschung<\/h2>\n<p>\t\t\t\t\t<span>ACE-031 is a recombinant fusion protein consisting of the extracellular ligand-binding domain of ActRIIB fused to human IgG1-Fc. ActRIIB is the primary type II receptor for multiple TGF-\u03b2 superfamily members. As a soluble decoy receptor, ACE-031 sequesters myostatin (GDF-8), activin A, activin B, GDF-11, and \u2014 critically \u2014 BMP-9 and BMP-10. In preclinical rodent and non-human primate models, systemic ACE-031 administration produces significant skeletal muscle mass increases and improvements in contractile function, attributable to broad-spectrum ActRIIB ligand neutralisation. Total serum FSH suppression in ACE-031-treated animals reflects near-maximal activin pathway inhibition and is a pharmacodynamic biomarker used in preclinical dose-response characterisation. The broad ActRIIB ligand trap profile also co-inhibits BMP-9 and BMP-10 \u2014 TGF-\u03b2 superfamily members involved in endothelial cell signalling \u2014 making this a relevant consideration in study design when vascular biology endpoints are being monitored. Supplied as lyophilised preparation (1 mg\/vial). Independently third-party HPLC-tested; COA available per batch.<\/span>\t\t\t\t\t<\/div>\n<div>\n<h2>FAQ<\/h2>\n<div>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>Why does ACE-031 differ from myostatin-selective inhibitors in research applications?<\/span><\/p>\n<\/summary>\n<div>\n<p>ACE-031 functions as a soluble ActRIIB ligand trap, binding multiple ActRIIB ligands including myostatin, activins, GDF-11, BMP-9, and BMP-10. This broad ligand-binding profile allows investigation of combined ActRIIB pathway suppression rather than isolated myostatin inhibition.<\/p>\n<p>In contrast, myostatin-selective approaches target GDF-8 specifically, making ACE-031 a valuable tool for studying the integrated contribution of multiple ActRIIB ligands to signalling, tissue regulation, and pathway cross-talk.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>How does ACE-031 differ from myostatin-specific antibodies?<\/span><\/p>\n<\/summary>\n<div>\n<p>ACE-031 acts upstream as a receptor-based ligand trap that sequesters multiple ActRIIB-binding growth factors, whereas myostatin-specific antibodies selectively neutralize GDF-8 alone. This distinction allows researchers to compare broad ActRIIB pathway inhibition with highly selective myostatin blockade and evaluate the biological consequences of each approach across different experimental systems.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What endpoints are commonly evaluated in ACE-031 research?<\/span><\/p>\n<\/summary>\n<div>\n<p>Common endpoints include skeletal muscle mass, muscle fibre morphology, muscle function measurements, ActRIIB pathway biomarkers, Smad2\/3 signalling activity, bone-related signalling markers, and expression of genes regulated by myostatin and activin pathways. These endpoints help characterize the effects of broad ActRIIB ligand sequestration and distinguish pathway-specific from multi-ligand responses.<\/p>\n<\/div>\n<\/details><\/div>\n<\/p><\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>ACE-031 (Ramatercept) is a soluble fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to a human IgG1-Fc region.<\/p>\n<p>Darreichungsform: ACE-031 1 mg.<\/p>\n<p>Gew\u00fcnschte St\u00e4rke und Packungsgr\u00f6\u00dfe ausw\u00e4hlen.<\/p>\n<p class=\"nm-research-disclaimer\">Nur f\u00fcr die Laborforschung. Nicht zur Anwendung bei Menschen oder Tieren.<\/p>\n<p class=\"nm-catalog-image-note\"><small>Mit KI erstellte illustrative Verpackung.<\/small><\/p>\n","protected":false},"featured_media":975,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[26],"product_tag":[],"nm_classification":[],"class_list":["post-812","product","type-product","status-publish","has-post-thumbnail","product_cat-recovery-regeneration","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"_links":{"self":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product\/812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/comments?post=812"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/media\/975"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/media?parent=812"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_brand?post=812"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_cat?post=812"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_tag?post=812"},{"taxonomy":"nm_classification","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/nm_classification?post=812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}